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Abstract
Background: The clinical course of Crohn’s disease (CD) and the effect of its treatment are monitored through
patient-reported signs and symptoms (S&S), and endoscopic evidence of inflammation. The Crohn’s Disease Patient-
reported Outcomes Signs and Symptoms (CD-PRO/SS) measure was developed to standardize the quantification of
gastrointestinal S&S of CD through direct report from patient ratings.
Methods: The CD-PRO/SS was developed based on data from concept elicitation (focus groups, interviews; n = 29),
then refined through cognitive interviews of CD patients (n = 20). Measurement properties, including item-level
statistics, scaling structure, reliability, and validity, were examined using secondary analyses of baseline and two-
week clinical trial data of adults with moderate-to-severe CD (n = 238).
Results: Findings from qualitative interviews identified nine S&S items covering bowel and abdominal symptoms.
The final CD-PRO/SS daily diary includes two scales: Bowel S&S (three items) and Abdominal Symptoms (three
items), each scored separately. Each scale showed evidence of adequate reliability (α = 0.74 and 0.67, respectively);
reproducibility (intraclass correlation coefficient > 0.80), and validity, with the last including moderate correlations
with the Inflammatory Bowel Disease Questionnaire bowel symptom score and select items (ranging from r = 0.43–
0.54). Scores distinguished patients categorized by patient global ratings of disease severity (p < 0.0001).
Conclusions: Results suggest the CD-PRO/SS is a reliable and valid measure of gastrointestinal symptom severity in
CD patients. Additional longitudinal data are needed to evaluate the ability of the CD-PRO/SS scores to detect
responsiveness and inform the selection of responder definitions.
Keywords: Crohn’s disease, Patient-reported outcome, Signs and symptoms, Reliability, Validity, Clinical trial
endpoints
Significance of this study
What is already known about this subject?
 The US Food and Drug Administration (FDA) has
established a pathway for rigorous development of
disease-specific Patient-reported Outcome (PRO)
tools for clinical trials and clinical use.
 Currently, there are no measures developed and
validated according to the FDA PRO guidance
available to assess the symptoms of Crohn’s disease
(CD).
What are the new findings?
 Using the US FDA pathway for rigorous
development of disease-specific PRO tools, we have
developed and validated a new patient-reported sign
and symptoms measure for clinical trials and clinical
use in CD.
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 This is the first symptom measure of CD to meet
US FDA PRO guidelines.
 This modular instrument can be used with
appropriate individual modules customized to the
mechanism of action of a candidate therapy, from
purely anti-inflammatory medications, to those tar-
geting pain, dysmotility, or functional symptoms.
How might it impact on clinical practice in the
foreseeable future?
 Using electronic device systems, PROs in CD can be
routinely measured before and between
appointments in order to identify response to
therapies or failure of therapies.
Background
Crohn’s disease (CD) is a type of inflammatory bowel
disease (IBD) that causes chronic inflammation of the
gastrointestinal (GI) tract. While the incidence and
prevalence of CD is subject to considerable variation
both between and within geographic regions, the highest
occurrence is generally in the developed countries of
North America and Europe [1]. A recent study estimates
that approximately 565,000 people in the United States
(US) have CD [2], with the prevalence in Europe varying
from 1.5 to 213 cases per 100,000 persons [1]. The inci-
dence of CD is increasing, with a global annual inci-
dence ranging from 3 to 20 per 100,000 person-years,
depending on geographic region [3]; currently the high-
est incidence of CD in Europe is 12.7 per 100,000
person-years and 20.2 per 100,000 person-years in North
America [4].
CD most commonly affects the most distal part of the
small intestine (ileum) and large intestine (colon), but
can develop in any part of the GI tract from the mouth
to the rectum. Patients who have active CD often experi-
ence abdominal pain, fatigue, and diarrhea. While the
cause of CD is unknown, risk factors include family his-
tory of the disease; it is most likely to present initially
between ages 15–30 with a second peak of onset at ages
50–70 [5].
Clinically, CD is monitored through signs and symp-
toms of disease activity and periodic objective assess-
ment, including endoscopy, imaging, or measurement of
biomarkers to evaluate mucosal inflammation. In clinical
trial settings, the Crohn’s Disease Activity Index (CDAI)
[6] score has been used to assess disease activity, com-
bining patient-reported signs and symptoms (loose/li-
quid stools, abdominal pain, general well-being) with
clinical assessments (i.e., complications, presence of ab-
dominal mass, change in weight, hematocrit levels, use
of antidiarrheal agents), using a weighted scoring
algorithm.
More recently, there has been growing interest for an
approach that discriminates between different aspects of
a disease, such as clinically derived signs, symptoms,
and/or clinical tests. The US Food and Drug Administra-
tion (FDA) released a guidance for the development of
Patient-Reported Outcome (PRO) measures to support
labeling claims for new medical treatments and products
[7]. This document emphasizes the importance of con-
ducting qualitative research among the target population
throughout the process of instrument development; this
is to ensure that the measure is consistent with the pa-
tient experience and covers what patients consider most
important about the condition and/or treatment inter-
vention. Quantitative work to assess the instrument’s
psychometric properties, such as reliability and validity,
is also recommended. This standard in instrument de-
velopment is increasingly seen as a regulatory require-
ment for efficacy evaluation and labeling purposes for
treatment interventions [7, 8]. For these reasons, a new
patient-reported sign and symptom measure for CD was
developed and validated according to the US FDA PRO
Guidance: this is the first symptom measure of CD to
meet these guidelines.
The Crohn’s Disease Patient-reported Outcomes (CD-
PRO) instrument was designed to comprehensively as-
sess the signs, symptoms, and impact of CD through six
modules. Modules 1 (Bowel Signs and Symptoms) and 2
(Abdominal Symptoms) comprise the CD-PRO Signs
and Symptoms (CD-PRO/SS) measure. Module 3 ad-
dresses Systemic Symptoms, Module 4 addresses Coping
Strategies, Module 5 addresses Daily Life Impact, and
Module 6 covers Emotional Impact. Any or all of these
modules may be used in any given study.
The focus of this paper is the CD-PRO/SS measure’s
ability to evaluate treatment-related outcomes and sup-
port labeling claims related to the GI signs and symp-
toms of CD in clinical trials of adults (age 18 or older)
with moderate-to-severe CD treated in outpatient set-
tings. This paper describes the development and initial
validation of this instrument. Given the day-to-day
symptom variability characteristic of CD, the CD-PRO/
SS is completed as a daily diary and is designed for elec-
tronic administration.
As noted throughout the paper, details related to the
CD-PRO/SS development and validation are provided in
the Additional file 1. Also included in this supplement is
information on the Systemic Symptoms scale (Module 3
of the CD-PRO), a five-item scale that can be included as
part of the daily diary to evaluate the non-gastrointestinal
systemic symptoms of CD. Based on the qualitative work,
these symptoms were found to be prevalent, relevant, and
important to the patient. However, systemic symptoms are
generally not affected by current gut-specific agents. From
a regulatory perspective, such symptoms are considered
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“distal” to the target disease activity and are therefore less
suitable for testing treatment effects and/or inclusion in a
product label. Because the intent is to develop the CD-
PRO/SS for use in drug development trials as a Drug De-
velopment Tool [9], Module 3 (Systemic Symptoms) is
not included in the CD-PRO/SS measure. At the discre-
tion of the user/sponsor, Module 3 can be administered as
part of the diary and serve as an exploratory assessment in
clinical trials. This scale may also be useful in studies or
clinical trials evaluating the systemic component of CD.
Information in the Additional file 1 is intended to facilitate
use of this Module.
Materials and methods
The research was conducted in two phases, consistent
with the methodology outlined in the US FDA PRO
Guidance [7]. Phase I addressed the content and struc-
ture of the measure and the documentation of content
validity through qualitative research methods. Phase II
addressed the quantitative properties of the measure, in-
cluding scoring and tests of reliability and validity, based
on a secondary analysis of baseline through Week 2
Phase II clinical trial data. All data collection and re-
cruitment procedures met institutional review board
(IRB) and Health Insurance Portability and Accountabil-
ity Act requirements and all applicable state and federal
laws and regulations, with study protocols approved by
an independent IRB and written informed consent ob-
tained from study subjects prior to completing any study
related activities.
Phase I: Qualitative – Development and content validity
A two-staged qualitative research process was used to
determine instrument content and structure, and to en-
sure clarity and understanding in the target patient
population. Focus groups and interviews were conducted
using a semi-structured discussion guide, informed by
clinical expert input and a review of the literature to
cross reference symptoms, and were audio-recorded and
transcribed for analysis. Additionally, participants com-
pleted a sociodemographic questionnaire for use in char-
acterizing the study sample. For both stages of the
qualitative research process, subjects were recruited
from US gastroenterology clinics and included ambula-
tory adult patients with clinician-confirmed CD based
on available biopsy. Patients participating in an interven-
tional study were excluded, as were those with an ileos-
tomy, colostomy, or an intra-abdominal surgery. Efforts
were made to recruit patients who represented a range
of disease activity, from mild to severe, based on the
Sandler estimated CD Activity Index [10].
Additional methods are outlined below, with details
provided in the online Additional file 1.
Stage 1: Focus groups and one-to-one interviews
Five focus groups (n = 20) and nine one-to-one qualita-
tive interviews were conducted to identify important CD
symptoms, explore the frequency and variability of these
symptoms, and inform the development of response op-
tions and appropriate recall for a symptom measure in
this target population. Subjects were recruited from
seven US clinical sites to represent a range of races, eth-
nicities, geographic locations, and disease activity. Dis-
cussion focused on participants’ current symptom
experiences, their experiences during an episode or
flare-up, and the impact of these symptoms on their
daily life.
Content analyses were performed by independent
coders, with data organized using qualitative software (i.
e., NVivo or ATLAS.ti). Participant quotes were grouped
and summarized by thematic code to assess saturation
of concepts. Saturation is defined as the point at which
no substantially new themes, descriptions of a concept,
or terms are introduced as additional discussions are
conducted [11].
Results were discussed with clinical experts and used
to generate a list of relevant symptoms, and a draft CD-
PRO/SS questionnaire, including instructions, items, and
response options.
Stage 2: Cognitive interviews
Two rounds of cognitive interviews (n = 20) were con-
ducted to examine the relevance, comprehensiveness,
and clarity of the draft CD-PRO/SS (including systemic
symptoms), and to refine the measure as needed. Sub-
jects were asked to complete the questionnaire inde-
pendently and were then interviewed about the content,
including instructions, recall period, candidate items,
and response options. Upon completion of 16 interviews
(Round 1), the instrument was edited for clarity based
on subject comments, and the revised instrument was
evaluated by a new sample of CD patients (Round 2, n =
4). Round 2 also provided an opportunity to examine pa-
tient understanding of the scales administered using an
electronic handheld device. Upon completion of this set
of interviews, the instrument was assessed for translata-
bility and finalized for quantitative testing.
Phase II: Quantitative – Score reliability and validity
A secondary analysis of data from a 24-week Phase II
clinical trial evaluating the efficacy of an experimental,
active treatment relative to placebo for the treatment of
moderate-to-severe CD was conducted to further exam-
ine the properties of the CD-PRO/SS. Baseline and
Week 2 data were used to determine the structure of the
measure and scoring, and to examine reliability and val-
idity. A total of 238 subjects were randomized to treat-
ment and included in this analysis. Adult patients, ages
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18–65, with a physician diagnosis of ileal, ileo-colonic,
or colonic CD a minimum of six months prior to the
baseline, with moderate-to-severe CD activity (CDAI
score ≥ 220 and ≤ 450) and inadequate response to, loss
of response to, or intolerance to either immunomodula-
tors or anti-tumor necrosis factor (TNF) agents were eli-
gible to participate in the study. Evidence of active
inflammation was required, as demonstrated by at least
one of the following: elevated C-reactive protein at
screening (≥ 5 mg/L); elevated fecal calprotectin at
screening (≥ 200 μg/g); or endoscopic evidence of in-
flammation within 12 weeks prior to baseline. Patients
with clinical manifestations of short bowel syndrome,
stricture with obstructive symptoms within three
months prior to baseline, or evidence of non-
inflammatory obstruction during the six months prior to
baseline were excluded from the study.
Measures
Subjects completed the CD-PRO/SS (9 candidate items)
and Module 3 Systemic Symptoms (5 candidate items)
throughout the study using an electronic hand-held de-
vice given to the subject upon enrollment, with training
provided by clinic site personnel. The daily diary scores
from Baseline through Week 2 were utilized in the
present analyses.
For score validation purposes, and to coincide with the
clinician assessment, the following paper-pen question-
naires were completed by subjects at the Baseline visit
(prior to seeing the clinician), and included in the ana-
lysis: the Inflammatory Bowel Disease Questionnaire
(IBDQ) [12] and the EuroQol Five-dimension Question-
naire Three-level Version (EQ-5D-3 L) [13]. In addition,
the score for patient-rated overall change in CD symp-
toms at Week 2 was utilized in the present analyses.
Clinicians completed the CDAI, with the baseline as-
sessment used for these analyses. In addition, a single-
item clinician-completed global rating of change (7-
point scale, ranging from “very much worse” to “very
much better”) in disease severity at Week 2 was included
in these analyses.
Statistical analysis
Analyses were performed in accordance with a pre-
specified statistical analysis plan. All statistical tests used a
significance level of 0.05 (two-sided) unless otherwise
noted. Statistical tests were adjusted for multiple compari-
sons as appropriate, using the Sheffe method. SAS version
9.2 was used for all statistical analyses, excepting the con-
firmatory factor analysis conducted with Mplus [14], and
the Rasch analysis conducted using RUMM2030 [15].
Item-level analyses were calculated using single-day
scores selected at random in the seven-day period leading
up to the baseline study visit. These analyses included
measures of central tendency, floor and ceiling effects,
and inter-item correlations. An item was flagged for po-
tential problems if it showed a floor (minimum response
> 25%) or ceiling effect (maximum response > 25%), or
when the inter-item correlation was greater than 0.80.
Factor analyses were performed to evaluate the structure
of the measure and develop a scoring algorithm. Approxi-
mation of simple structure with factor loadings greater
than 0.30 were the criterion for accepting a factor solu-
tion; oblique rotation was allowed. Rasch analyses were
conducted separately for each factor that consisted of a
single dimension; items with negative fit residual value ≤
− 3.0 or positive fit residual ≥3.0 were flagged for potential
deletion [16]. Factor and Rasch analyses were conducted
using single-day scores selected at random using SAS ver-
sion 9.2 from the week leading up to the Week 2 visit.
Once the items and scales were finalized, scores were
tested for reliability and validity using Baseline and/or
Week 2 data. Specifically, internal consistency reliability
was assessed using Cronbach’s alpha coefficient, with a
target value of 0.7 indicating good internal consistency
[17, 18]. Test-retest reliability was assessed among those
who reported relative stability in their condition over a
two-week period (Baseline to Week 2) in two different
ways. In the first analysis, test-retest reliability was
assessed among subjects who reported relative stability
in patient-reported global rating of change (i.e., “almost
the same” or “about the same”). In the second analysis,
test-retest reliability was assessed among those with no
change based on a clinician-rated global raging of
change in CD severity at Week 2. Intraclass correlation
coefficients (ICC) were computed, whereby ≥0.7 indi-
cates good test-retest reliability [18, 19].
Score validity was assessed by examining correlations
of the CD-PRO/SS with the IBDQ scores and EQ-5D-
3 L scores at Baseline using Spearman rank correlations.
The CD-PRO/SS was expected to be moderately to
highly correlated (> 0.40) [20] with IBDQ scores. No
specific hypotheses were made with respect to the mag-
nitude of the correlations between the CD-PRO/SS
scores and the EQ-5D-3 L, although generally lower cor-
relations were expected relative to those specified above,
given that the EQ-5D-3 L is a generic health status
measure as opposed to a specific measure of the signs
and symptoms of CD.
Known-group validity was examined to determine
whether the CD-PRO/SS could distinguish between pa-
tients by disease severity based on the patient-rated global
assessment of disease severity, with mean CD-PRO/SS
scores at Baseline compared by patient global scores cate-
gorized by “not at all” vs. “very mild,” “mild” vs. “moder-
ate,” and “severe” vs. “very severe.” Analysis of covariance
models with baseline clinical measurement groups as the
main effects in the model were used.
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Results
Study samples
Demographics and clinical characteristics for the qualita-
tive studies are shown in Table 1. The study samples
ranged in age from 19 to 72, representing a range in
terms of ethnicity, race, extent of disease, and disease
severity.
Phase I: Development and content validity
Findings from focus groups and individual interviews
identified nine sign and symptom items covering bowel
and abdominal symptoms. Important bowel-related
symptoms from the perspective of the patient included
frequency, consistency, the presence of blood, and the
urge/need to have a bowel movement (BM) right away.
Key abdominal symptoms included pain in the stomach
area, bloating, gas, nausea, and vomiting. The symptoms
most relevant during flare-ups included frequency of
and consistency of BMs, and pain in the stomach area.
Patient descriptions of the symptoms they experienced
during a flare were similar to the language they used to
describe their everyday symptoms, just more severe and/
or persistent. Patient descriptions of their symptom ex-
perience underline the variability not only within, but
also between patients.
Additional details of the qualitative methods and re-
sults, along with evidence of saturation, are shown in
the online Additional file 1.
The final version, ready for quantitative testing, was a
daily diary comprising nine candidate symptom items
covering all GI signs and symptoms identified by pa-
tients and confirmed by clinicians as relevant and im-
portant to the assessment of disease activity in CD. For
number and consistency of bowel movements, response
options were based on frequency. The number of bowel
movements was queried on a 8-point scale with ranges
considered reasonable and meaningful to patients and
clinicians (0, 1–2, 3–4, 5–6, 7–9, 10–12, 13–17, 18–24,
more than 24). The intent was to use quantitative data
to evaluate these categories, with the possibility of com-
bining and/or deleting categories, while maintaining a
clinically meaningful and sensitive indicator of bowel
movement frequency. For all other symptoms, response
options were based on presence (yes/no) and severity or
frequency of each, with scores ranging from 0 (none or
not at all) to 4 (always or very severe); scores for the
item “vomiting” ranged from 0 times to 4 or more times.
Phase II: Score reliability and validity
Item and factor analysis and scoring algorithm
Item-by-item descriptive statistics are reported in Table 2.
Subjects used the full range of response options for each
of the items, with the exception of the item concerning
number of bowel movements; no study participants
reported > 24 bowel movements for the single-day scores
selected at random. Four of nine items had a floor effect
exceeding 25%, with more than 65% of patients reporting
no vomiting (97.1%), no blood in bowel movement (76.
5%), and no nausea (60.9%). Ceiling effects (> 25%) were
considered high for only the number of liquid bowel
movements (38.2%).
Due to the notable floor effects, items assessing the
concepts of vomiting, blood in bowel movement, and
nausea were deleted from the exploratory factor analysis
model. After these three items were deleted, the findings
support a two-factor solution (Comparative Fit Index =
0.98, Standardized Root Mean Square Residual = 0.033,
and Root Mean Square of Approximation = 0.094).
One factor represents “Bowel Signs and Symptoms”
and includes three items (number of BMs, BMs mostly
or completely liquid, and urge to have BMs right away),
while the other factor represents “Abdominal Symp-
toms” and also includes three items (pain in belly, bloat-
ing, and pass gas). Rasch analysis indicated that all of
the fit residuals for items in each of the two models fell
within the acceptable range (≥ − 3.0 and ≤ 3.0); however,
several of the response categories were not ordered cor-
rectly, primarily due to very few responses for “rarely”
and “mild” categories.
Taking into consideration findings from both the
qualitative and quantitative studies, several decisions
were reached regarding the CD-PRO/SS. First, given that
few subjects endorsed the response category “more than
24” for the item “number of BMs,” this item response
level was removed. As noted previously, three items
(vomiting, blood in bowel movement, and nausea) were
deleted due to high floor effects. Finally, although the
Rasch analyses suggested the number of response op-
tions for several items could be reduced from a 5- to a
4-point scale by combining responses, the distinction be-
tween “none” and “mild” and between “mild” and “mod-
erate” was considered clinically important and the
decision was made to retain the 5-point scaling.
The final CD-PRO/SS assesses two important indica-
tors of disease activity in CD: Bowel Signs and Symp-
toms (three items) and Abdominal Symptoms (three
items), with each scored as a simple mean across all
items comprising the scale. There is no single total score
that combines both scales.
Reliability
Adequate internal consistency reliability was demon-
strated with alpha coefficients of 0.74 for Bowel Signs
and Symptoms and 0.67 for Abdominal Symptoms. Al-
though findings indicate that the Cronbach’s alpha for
the domain of Abdominal Symptoms would increase
slightly to 0.69 with the deletion of “passing gas,” the
item was retained based on importance of this symptom
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Table 1 Patient Demographic and Clinical Characteristics: Phase I, Qualitative
Demographic and Clinical Characteristics Total (n = 49)
Age






Hispanic or Latino 2 (4.1%)
Not Hispanic or Latino 46 (93.9%)
Missing 1 (2.0%)
Race,a n (%)
American Indian or Alaska Native 0 (0.0%)
Asian 1 (2.0%)
Black or African American 5 (10.2%)




Mean (SD) 470.8 (262.82)
Range (42–1078)
Remission (< 150) 5 (10.2%)
Mild (150–220) 3 (6.1%)
Moderate (≥ 220) 41 (83.7%)
Extent of disease, n (%)
Affecting only the colon (large intestine) 14 (28.6%)
Affecting only the lower small intestine (ileum and jejunum) 6 (12.2%)
Affecting only the upper GI tract (stomach, esophagus, and duodenum) 0 (0.0%)
Affecting the colon (large intestine) and lower small intestine 22 (44.9%)
Affecting the lower small intestine and upper GI tract 3 (6.1%)
Affecting the colon (large intestine), and the lower small intestine, and the upper GI tract (stomach, esophagus, and duodenum) 4 (8.2%)
Disease location,b n (%)
L1, ileal only 4 (13%)
L2, colonic only 13 (43%)
L3, ileocolonic 12 (40%)
L4, isolated upper disease –
Missing 1 (3%)
Disease behavior,b,c n (%)
B1, non-stricturing non-penetrating 14 (47%)
B2, stricturine 11 (37%)
B3, penetrating (not including abscess) 6 (20%)
Note: Percents may not add to 100 due to rounding
aNot mutually exclusive
bData were only collected for additional concept elicitation and cognitive interview (n = 30)
cResponses are not mutually exclusive
Abbreviations: n Number, SD Standard deviation, SeCDAI Sandler estimated Crohn’s disease Activity Index
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from the patient perspective. Test-retest reliability in
stable patients was supported by both patient-reported
change in symptom (n = 110) and clinician-reported
change in symptom severity (n = 126) over a two-week
period, with ICC values > 0.80 for both scales.
Validity
Correlations between the CD-PRO/SS domain scores
and other relevant PRO measures are presented in
Table 3. All relationships were confirmed based on a
priori predictions, with CD-PRO/SS Bowel Signs and
Symptoms domain score demonstrating moderate corre-
lations with IBDQ bowel frequency item (r = 0.43), and
the CD-PRO/SS Abdominal Scale domain score demon-
strating moderate correlations with the IBDQ bloating
items (r = 0.54) and the IBDQ bowel system score (r = 0.
48). As anticipated, weaker correlations were observed
between the CD-PRO/SS scales with measures of IBDQ
emotional health and social functions scores (discrimin-
ant validity) and the EQ-5D-3 L scores.
The Bowel Signs and Symptoms and Abdominal
Symptoms Scales were each able to significantly
differentiate among the moderate and severe groups as
defined by patient ratings of their symptom severity (p <
0.05). Pairwise comparisons that included the mild and
very severe disease severity groups were not statistically
significantly different for either of the CD-PRO/SS
scales.
Discussion
The CD-PRO/SS measure was developed to standardize
the quantification of GI signs and symptoms of CD in
clinical trials through direct patient ratings. The meth-
odology used to develop the CD-PRO/SS followed the
US FDA Guidance on PRO instrument development,
which conveys the agency’s thinking on best practices
for the development of measures and the evidence
needed for the agency’s evaluation [7]. The position of
the US FDA is that the CDAI is no longer an acceptable
measure to assess the signs and symptoms of CD for la-
beling purposes and that these concepts are best mea-
sured, scored, and reported independently, separating
clinical findings from patient-reported symptoms, with
the latter coming directly from the patients themselves
Table 2 Item Descriptive Characteristics CD-PRO/SSa (n = 238)
CD Signs and Symptoms Mean (SD) Range Floor, N (%) Ceiling, N (%)
Number of bowel movements 4.1 (1.47) 1–8 7 (2.9%) 0 (0.0%)
Number of liquid bowel movements 2.8 (1.28) 0–4 21 (8.8%) 91 (38.2%)
Blood in bowel movements 0.6 (1.18) 0–4 182 (76.5%) 11 (4.6%)
Passing gas 2.0 (1.23) 0–4 41 (17.2%) 23 (9.7%)
Vomiting 0.1 (0.39) 0–4 231 (97.1%) 1 (0.4%)
Pain in belly 2.1 (1.16) 0–4 32 (13.4%) 26 (10.9%)
Feel nauseated 0.9 (1.21) 0–4 145 (60.9%) 7 (2.9%)
Bloating 1.7 (1.30) 0–4 71 (29.8%) 18 (7.6%)
Need to have bowel movement right away 2.2 (1.36) 0–4 49 (20.6%) 45 (18.9%)
aCD-PRO single-day item score which is selected at random from the non-missing days in the week preceding baseline visit.Abbreviations: CD-PRO/SS Crohn’s dis-
ease patient-reported outcome symptoms and signs, n Number
Table 3 Construct Validity: CD-PRO/SS Score Correlationsa with IBDQ Scores at Baseline















BM Scale .43 .06 .08 .26 .09 .10 .19
Number of bowel movements .37 .15 .07 .14 .02 .03 .15
Mostly liquid bowel movements .32 .08 .01 .16 .14 .02 .10
Need to have bowel movement
right away
.35 .04 .10 .29 .09 .15 .14
Abdominal Scale .15 .54 .02 .48 .27 .26 .24
Pass gas .17 .26 .06 .30 .10 .20 .13
Pain in belly .14 .25 .06 .38 .30 .15 .23
Bloating .07 .69 .01 .43 .26 .27 .20
aSpearman’s correlation coefficient
Abbreviations: CD-PRO/SS Crohn’s disease patient-reported outcome signs and symptoms, IBDQ Inflammatory Bowel Disease Questionnaire, p p-value, r Rating
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using a reliable and valid measure fit for this purpose [7,
21–23]. The European Medicines Agency also discour-
ages the use of the CDAI as a primary endpoint for fu-
ture clinical studies, and instead recommends that signs,
symptoms, and inflammation be evaluated independ-
ently [24]. While items derived from the CDAI (includ-
ing stool frequency and abdominal pain) are currently
being used in clinical trials, these PRO measures are
meant for interim use only to ensure that new drug ther-
apies can progress [25, 26]. The CD-PRO/SS represents
a new measure to evaluate treatment-related outcomes
from the perspective of the patient and to support label-
ing claims related to the GI signs and symptoms of CD
in clinical trials of adults (age 18 or older) with
moderate-to-severe CD treated in outpatient settings.
The CD-PRO/SS was developed based on data col-
lected from focus groups and one-to-one concept elicit-
ation interviews, input from clinical experts, and refined
through a process of cognitive interviews, all with repre-
sentatives of the target population. Every effort was
made to ensure that the qualitative phase of research
was conducted in a manner that was conclusive with re-
spect to concept elicitation and that sufficient cognitive
interviews were conducted to ensure that comprehen-
sion and readability were acceptable. Measurement
properties were tested based on a secondary analysis of
clinical trial data of 238 adults with moderate-to-severe
CD.
The decision to retain or delete items for the final
measure was an iterative process with consideration of
floor and ceiling effects, results from the factor and
Rasch analyses, previous qualitative results, and clinical
considerations. Several items included in the Bowel
Signs and Symptoms and Abdominal Symptoms Scales
had high floor effects (> 30%), most notably vomiting,
blood in bowel movement, and nausea, and were subse-
quently deleted from the CD-PRO/SS. Results of the
Rasch analyses of response options suggests that there is
little response distinction between “none” and “mild” or
between “never” and “rarely.” These responses were
retained, however, given the importance of the response
distinction from a clinical perspective, to capture degrees
of improvement in more severe patients, with the under-
standing that further evaluation will be needed to con-
firm their suitability and utility across populations.
The final CD-PRO/SS includes two scales: Bowel Signs
and Symptoms (three items) and Abdominal Symptoms
(three items), with both scales scored separately. Per-
formance testing of the CD-PRO/SS scores demon-
strated evidence of internal consistency and
reproducibility. The CD-PRO/SS scores showed moder-
ate correlations with other relevant measures identified
a priori. The CD-PRO/SS scores also appear to have
known-group validity with significant differences in both
domain scores between moderate and severe disease
groups when defined by patient global ratings of disease
severity. Pairwise comparisons that included the mild
and very severe severity groups were not statistically sig-
nificantly different, due in large part to the small sample
size in the mild (n = 7) and very severe (n = 20) groups at
baseline.
Both scales of the CD-PRO/SS include multiple items
to better capture the bowel and abdominal symptom ex-
perience of CD from the perspective of the patient,
which allows for a more granular assessment of aspects
of the disease that are relevant and important to pa-
tients. In clinical trials of therapies for CD, the CD-
PRO/SS potentially can provide data for a co-primary
endpoint or a key secondary endpoint. Therapies target-
ing inflammation in induction studies could use an ob-
jective marker of inflammation (e.g., endoscopy,
magnetic resonance enterography, fecal calprotectin) to
assess the co-primary or primary endpoint, with the
Bowel Signs and Symptoms module as the assessment of
a co-primary or key secondary endpoint. Therapies ex-
pected to improve functional abdominal symptoms
might use this module as the primary endpoint, while
maintenance studies of anti-inflammatory studies might
use a co-primary endpoint of an objective marker of in-
flammation and the Bowel Signs and Symptoms and Ab-
dominal Symptoms scales to demonstrate a long-term
significant impact on multiple symptom domains im-
portant to patients.
Several limitations should be noted for this research.
First, the sample included a predominance of patients
with moderate-to-severe CD, due to inclusion criteria
for the clinical study which required patients to have a
CDAI score ≥ 220 and ≤ 450. In general, CD clinical trials
enroll patients whose disease severity is moderate to se-
vere at baseline disease severity, so as to be able to
evaluate improvement during the entire treatment
period. While these patients represent the target popula-
tion for the final CD-PRO/SS, it is generally best to in-
clude subjects with a full range of disease severity in
psychometric evaluation studies to optimize testing and
assure consistent score performance across this overall
range in severity. In addition, only two weeks of clinical
trial data were available for analysis, precluding the
evaluation of responsiveness to change in clinical status.
In conclusion, the CD-PRO/SS is a new daily diary to
gather data on the gastrointestinal signs and symptoms
of CD directly from the patient. The instrument was de-
veloped to meet regulatory guidance, with initial valid-
ation evidence suggesting that the CD-PRO/SS scores
are reliable, valid, and ready for use and further testing
in clinical trials. The CD-PRO/SS complements and ex-
tends information provided by the clinician, endoscopy,
and biomarkers in clinical studies.
Higgins et al. Journal of Patient-Reported Outcomes  (2018) 2:24 Page 8 of 10
Additional file
Additional file 1: Development and validation of the Crohn’s Disease
Patient-reported Outcomes Signs and Symptoms (CD-PRO/SS) Diary.
(DOCX 117 kb)
Abbreviations
BM: Bowel movement; CD: Crohn’s disease; CDAI: Crohn’s Disease Activity
Index; CD-PRO: Crohn’s Disease Patient-reported Outcomes; CD-PRO/
SS: Crohn’s Disease Patient-reported Outcomes Signs and Symptoms; EQ-5D-
3 L: EuroQol Five-dimension Questionnaire Three-level Version; FDA: Food
and Drug Administration; GI: Gastrointestinal; IBD: Inflammatory bowel
disease; IBDQ: Inflammatory Bowel Disease Questionnaire; ICC: Intraclass
correlation coefficients; IRB: Institutional review board; PRO: Patient-reported
outcomes; SD: Standard deviation; SeCDAI: Sandler estimated Crohn’s disease
Activity Index; SS: Signs and symptoms; TNF: Anti-tumor necrosis factor;
US: United States
Acknowledgements
The authors wish to thank the following for their assistance with conducting
focus groups and contribution to the early development of the CD-PRO: Pa-
tricia A. Wren, Oakland University, Rochester, MI; Taft Bhuket of Alameda
County Medical Center, Oakland, CA; Carrie Bergmans, University of Michigan,
Ann Arbor, MI; Raymond Cross, University Maryland, College Park, MD; Kim
Isaacs, University of North Carolina, Chapel Hill, NC; Michael Docherty of Uni-
versity of California San Diego, San Diego, CA.
The authors also wish to thank Anne Brooks, Zaneta Balantac, and Sara
Gleeson of Evidera for their assistance with qualitative interviews conducted
in Phase I and data collection conducted in Phase II; Ren Yu for SAS
programming, and Randall Bender for statistical and analytic support.
Funding
The IBD PRO Consortium is an academic-industry consortium funded by
Amgen Inc. and Genentech Inc., in collaboration with Dr. Peter Higgins at
the University of Michigan Health Systems, to develop patient-reported out-
comes (PRO) drug development tools (DDT) for clinical trials that evaluate
the treatment efficacy of IBD, specifically Crohn’s disease (COA DDT# 000034)
and ulcerative colitis (COA DDT# 000040).
Availability of data and materials
The data collected during this study is kept in a locked, secure facility and is
unavailable to the public due to confidentiality concerns. Reasonable
requests to review the data for scientific and/or research purposes may be
considered.
Authors’ contributions
Gale Harding was the primary writer of this manuscript, and she directed the
study including the study design, data analysis, and data interpretation. Peter
D.R. Higgins, Nancy K. Leidy, Kendra DeBusk, Donald L. Patrick, Hema N.
Viswanathan, Kristina Fitzgerald, Sarah M. Donelson, Marcoli Cyrille, Brian G.
Ortmeier, Hilary Wilson, Dennis A. Revicki, and Gary Globe made substantial
contributions to the study design, data interpretation, and resulting
manuscript. All authors provided input on multiple drafts of the manuscript
and approval of the final draft.
Ethics approval
This study was a secondary analysis of clinical trial data. Written informed
consent was obtained from all study subjects who participated in the clinical
trial, and the study protocol was approved by the Institutional Review Board
at each study site.
Competing interests
Corresponding author Peter D.R. Higgins is the Director of the IBD Program
at the University of Michigan in Ann Arbor, MI. Authors Marcoli Cyrille, Brian
G. Ortmeier, and Gary Globe are salaried employees and shareholders of
Amgen Inc. (Thousand Oaks, CA). Author Hema N. Viswanathan was a
salaried employee and shareholder of Amgen Inc. of Thousand Oaks, CA at
the time this work was completed, and is currently with Allergan Inc. of
Irvine, CA. Author Donald L. Patrick is employed by the University of
Washington (Seattle, WA). Authors Kendra DeBusk, Kristina Fitzgerald, and
Sarah M. Donelson are salaried employees and shareholders of Genentech
Inc. (South San Francisco, CA). Authors Gale Harding, Nancy Leidy, Hilary
Wilson, and Dennis Revicki are salaried employees of Evidera in Bethesda,
MD, and are not allowed to accept remuneration from any clients for their
services. Evidera received funding from Amgen Inc. (Thousand Oaks, CA) to
participate in the study and the development of this manuscript.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1University of Michigan, Ann Arbor, MI, USA. 2Evidera, Bethesda, MD, USA.
3Genentech Inc., South San Francisco, CA, USA. 4University of Washington,
Seattle, WA, USA. 5Amgen Inc., Thousand Oaks, CA, USA. 6IBD Program
University of Michigan, SPC 5682, 1650 West Medical Center Drive, Ann
Arbor, MI 48109, USA. 7Present address: Allergan Inc., Irvine, CA, USA.
Received: 15 November 2017 Accepted: 3 April 2018
References
1. Burisch, J., Jess, T., Martinato, M., Lakatos, P. L., & EpiCom, E. (2013). The
burden of inflammatory bowel disease in Europe. Journal of Crohn's &
Colitis, 7, 322–337.
2. Kappelman, M. D., Moore, K. R., Allen, J. K., & Cook, S. F. (2013). Recent trends
in the prevalence of Crohn's disease and ulcerative colitis in a commercially
insured US population. Digestive Diseases and Sciences, 58, 519–525.
3. M'Koma, A. E. (2013). Inflammatory bowel disease: An expanding global
health problem. Clin Med Insights Gastroenterol, 6, 33–47.
4. Ye, Y., Pang, Z., Chen, W., Ju, S., & Zhou, C. (2015). The epidemiology and
risk factors of inflammatory bowel disease. International Journal of Clinical
and Experimental Medicine, 8, 22529–22542.
5. Baumgart, D. C., & Sandborn, W. J. (2007). Inflammatory bowel disease:
Clinical aspects and established and evolving therapies. Lancet, 369, 1641–
1657.
6. Best, W. R., Becktel, J. M., Singleton, J. W., & Kern Jr., F. (1976). Development
of a Crohn's disease activity index. National Cooperative Crohn's Disease
Study Gastroenterology, 70, 439–444.
7. Food and Drug Administration (2009). Guidance for industry—Patient-
reported outcome measures: Use in medical product development to
support labeling claims. Available at: http://www.fda.gov/downloads/Drugs/
Guidances/UCM193282.pdf. Fed Regist, 74, 65132–65133.
8. Spiegel, B. M., Bolus, R., Agarwal, N., Sayuk, G., Harris, L. A., Lucak, S., Esrailian,
E., Chey, W. D., Lembo, A., Karsan, H., Tillisch, K., Talley, J., & Chang, L. (2010).
Measuring symptoms in the irritable bowel syndrome: Development of a
framework for clinical trials. Alimentary Pharmacology & Therapeutics, 32,
1275–1291.
9. FDA and CDER (2014) Guidance for industry and FDA staff: Qualification
process for drug development tools. Available at: https://www.fda.gov/
downloads/drugs/guidances/ucm230597.pdf.
10. Sandler, R. S., Jordan, M. C., & Kupper, L. L. (1988). Development of a Crohn's
index for survey research. Journal of Clinical Epidemiology, 41, 451–458.
11. Leidy, N. K., & Vernon, M. (2008). Perspectives on patient-reported outcomes:
Content validity and qualitative research in a changing clinical trial
environment. PharmacoEconomics, 26, 363–370.
12. Guyatt, G., Mitchell, A., Irvine, E. J., Singer, J., Williams, N., Goodacre, R., &
Tompkins, C. (1989). A new measure of health status for clinical trials in
inflammatory bowel disease. Gastroenterology, 96, 804–810.
13. EuroQol Group. (1990). EuroQol–a new facility for the measurement of
health-related quality of life. Health Policy, 16, 199–208.
14. Muthén, L. K., & Muthén, B. O. (1998-2010). Mplus user’s guide. Los Angeles:
Muthén & Muthén.
15. Andrich, D., Lyne, A., Sheridan, B., & Luo, G. (2012). RUMM 2030: Rasch
Unidimensional measurement models. Australia: RUMM Laboratory Try Ltd..
16. Rasch, G. (1980). Probabilistic models for some intelligence and attainment
tests. Chicago: University of Chicago Press.
17. Cronbach, L. J. (1951). Coefficient alpha and the internal structure of tests.
Psychometrika, 16, 297–334.
18. Nunnally, J. C., & Bernstein, I. H. (1994). Psychometric theory. New York:
McGraw-Hill.
Higgins et al. Journal of Patient-Reported Outcomes  (2018) 2:24 Page 9 of 10
19. Leidy, N. K., Revicki, D. A., & Geneste, B. (1999). Recommendations for
evaluating the validity of quality of life claims for labeling and promotion.
Value in Health, 2, 113–127.
20. Cohen, J. (1988). Statistical power analysis for the behavioral sciences.
Hillsdale: Lawrence Erlbaum Associates Inc..
21. Food and Drug Administration (FDA). (2012). Gastroenterology regulatory
endpoints and the advancement of therapeutics (GREAT I) Workshop. College
Park, Food and Drug Administration, Center for Drug Evaluation and
Research.
22. Food and Drug Administration (FDA). (2013). Gastroenterology regulatory
endpoints and the advancement of therapeutics (GREAT II) Workshop.
Bethesda: Food and Drug Administration, Center for Drug Evaluation and
Research.
23. Food and Drug Administration (FDA). (2015). Gastroenterology regulatory
endpoints and the advancement of therapeutics (GREAT III) Workshop. Silver
Spring: Food and Drug Administration, Center for Drug Evaluation and
Research.
24. European Medicines Agency (EMA) (2016). Guideline on the development
of new medicinal products for the treatment of Crohn's disease (Draft).
London: European Medicines Agency. Available at: http://www.ema.europa.
eu/docs/en_GB/document_library/Scientific_guideline/2016/07/
WC500211430.pdf.
25. Gasink, C., Friedman, J., Gao, L. L., Chan, D., Sandborn, W. J., & Feagan, B.
(2015). Evaluation of an interim Crohn's disease outcome measure (PRO-2)
based on two patient-reported components (stool frequency, abdominal
pain) of the Crohn's disease activity index (CDAI) in the ustekinumab
CERTIFI study. 10th congress of European Crohn's and colitis organization
(ECCO-2015); 18–21 February 2015; Barcelona.
26. Khanna, R., Zou, G., D'Haens, G., Feagan, B. G., Sandborn, W. J., Vandervoort,
M. K., Rolleri, R. L., Bortey, E., Paterson, C., Forbes, W. P., & Levesque, B. G.
(2015). A retrospective analysis: The development of patient reported
outcome measures for the assessment of Crohn's disease activity. Alimentary
Pharmacology & Therapeutics, 41, 77–86.
Higgins et al. Journal of Patient-Reported Outcomes  (2018) 2:24 Page 10 of 10
